

ramR Mutations Involved in Efflux-Mediated Multidrug Resistance in *Salmonella enterica* Serovar Typhimurium[∇]

Yousef M. Abouzeed, Sylvie Baucheron, and Axel Cloeckae^{*}

INRA, UR1282, Infectiologie Animale et Santé Publique, IASP, Nouzilly F-37380, France

Received 21 January 2008/Returned for modification 1 April 2008/Accepted 21 April 2008

In the sequenced genome of *Salmonella enterica* serovar Typhimurium strain LT2, an open reading frame (STM0580) coding for a putative regulatory protein of the TetR family is found upstream of the *ramA* gene. Overexpression of *ramA* results in increased expression of the AcrAB efflux pump and, consequently, multidrug resistance (MDR) in several bacterial species. The inactivation of the putative regulatory protein gene upstream of *ramA* in a susceptible serovar Typhimurium strain resulted in an MDR phenotype with fourfold increases in the MICs of unrelated antibiotics, such as quinolones/fluoroquinolones, phenicols, and tetracycline. The inactivation of this gene also resulted in a fourfold increase in the expression of *ramA* and a fourfold increase in the expression of the AcrAB efflux pump. These results indicated that the gene encodes a local repressor of *ramA* and was thus named *ramR*. In contrast, the inactivation of *marR*, *marA*, *soxR*, and *soxS* did not affect the susceptibilities of the strain. In quinolone- or fluoroquinolone-resistant strains of serovar Typhimurium overexpressing AcrAB, several point mutations which resulted in amino acid changes or an in-frame shift were identified in *ramR*; in addition, mutations interrupting *ramR* with an IS1 element were identified in high-level fluoroquinolone-resistant serovar Typhimurium DT204 strains. One serovar Typhimurium DT104 isolate had a 2-nucleotide deletion in the putative RamR binding site found upstream of *ramA*. These mutations were confirmed to play a role in the MDR phenotype by complementing the isolates with an intact *ramR* gene or by inactivating their respective *ramA* gene. No mutations in the *mar* or *sox* region were found in the strains studied. In conclusion, mutations in *ramR* appear to play a major role in the upregulation of RamA and AcrAB and, consequently, in the efflux-mediated MDR phenotype of serovar Typhimurium.

Fluoroquinolones, together with extended-spectrum cephalosporins, are the treatment of choice for nontyphoid salmonellosis, as stable resistance to the most common members of different families of antimicrobial agents (ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline) has developed during the 1990s with the epidemic *Salmonella enterica* serovar Typhimurium phage type DT104 (8, 10, 21, 31). Emerging resistance to fluoroquinolones in *Salmonella* spp. has been reported for both human and animal cases and is thus threatening to become a serious public health problem (8, 10, 21, 31).

In *Salmonella* spp., quinolone and fluoroquinolone resistance has been attributed to point mutations in the quinolone resistance-determining regions (QRDRs) of the target genes *gyrA*, *gyrB*, *parC*, and *parE*. For the *gyrA* gene, coding for the A subunit of DNA gyrase, whose complex with DNA is the primary target of quinolones, mutations resulting in amino acid changes at Ser83 (to Phe, Tyr, or Ala) or at Asp87 (to Gly, Asn, or Tyr) are the most frequently observed in nalidixic acid-resistant strains (8, 10, 21, 31). Double mutations at both residues 83 and 87 have been identified in clinical isolates of serovar Typhimurium DT204 showing high-level resistance to fluoroquinolones, together with one mutation leading to the amino acid change Ser464Phe in the QRDR of *gyrB*, encoding the B subunit of DNA gyrase, and one mutation leading to the

amino acid change Ser80Ile in the QRDR of *parC*, coding for the ParC subunit of topoisomerase IV, the secondary target of quinolones (4, 5).

Fluoroquinolone resistance in serovar Typhimurium has also been attributed to an active efflux mechanism (8, 10, 11, 22), and we have recently reported the participation of the AcrAB-TolC efflux system as an important mechanism of high-level resistance to fluoroquinolones in serovar Typhimurium DT204 as well as an important mechanism of both multidrug resistance (MDR) and quinolone resistance in serovar Typhimurium DT104 (4, 5, 6). High-level resistance to fluoroquinolones in *Salmonella* is thus essentially explained by the combination of two major resistance mechanisms, i.e., multiple target gene mutations and active efflux.

The expression of *acrAB*, encoding the major AcrAB efflux pump, is subject to multiple levels of regulation. In *Escherichia coli*, it is modulated at the lowest level by the local repressor AcrR. At a more global level, *acrAB* expression is modulated by stress conditions and by global regulators like MarA, SoxS, or Rob (1, 2, 3, 14, 16). The *acrAB* locus is indeed part of the *mar*, *sox*, and *rob* regulons of *E. coli*, whose activation confers a low level of resistance to a wide range of antimicrobial agents and organic solvents. Proteins encoded by the *mar* locus include the transcriptional activator MarA, its local repressor MarR, and two proteins with unknown functions, MarB and MarC. MarR negatively regulates the expression of *marRAB* by binding to the *marO* operator region. Proteins encoded by the *soxRS* locus include the transcriptional activator SoxS and a protein, SoxR, whose oxidized form can activate *soxS* expression.

While these regulator systems have been well studied in *E.*

^{*} Corresponding author. Mailing address: Unité Infectiologie Animale et Santé Publique site 213, Institut National de la Recherche Agronomique, 37380 Nouzilly, France. Phone: 33-(0)2 47 42 77 50. Fax: 33-(0)2 47 42 77 74. E-mail: cloeckae@tours.inra.fr.

[∇] Published ahead of print on 28 April 2008.

coli, less is known about their role in *Salmonella* spp. Moreover, in *Salmonella* spp. and in other bacteria, such as *Enterobacter aerogenes*, *Enterobacter cloacae*, and *Klebsiella pneumoniae*, RamA, a homologue of MarA that is absent in *E. coli*, has been shown to be implicated in MDR, and the overexpression of *ramA* correlated well with an increased expression of the AcrAB efflux pump (7, 12, 13, 27–30, 33).

In previous studies, we investigated whether mutations in regulatory regions like *acrR*, *marRAB*, or *soxRS*, in addition to target gene mutations (*gyrA*), could participate in the fluoroquinolone and MDR phenotype of serovar Typhimurium overproducing AcrAB (19, 20). However, only mutations in the *acrR* gene of in vitro fluoroquinolone-selected serovar Typhimurium mutants were identified (19). Therefore, in this study, we investigated the roles of MarR, MarA, SoxR, SoxS, and RamA in the MDR and quinolone resistance of serovar Typhimurium. We investigated particularly the role of the putative local repressor of RamA, which belongs, according to amino acid sequence homology, to the TetR family of proteins and whose gene is found upstream of *ramA* in the opposite orientation in the serovar Typhimurium LT2 genome (Fig. 1). This putative local repressor has not yet been reported to occur in *Salmonella* and other bacteria. Therefore, we also investigated the presence of mutations in the putative repressor gene and in the regulatory region of *ramA* that could explain the overproduction of RamA and, consequently, of AcrAB in MDR and quinolone-resistant serovar Typhimurium.

MATERIALS AND METHODS

Bacterial strains. All strains studied are listed in Table 1. MDR serovar Typhimurium DT104 strains were isolated from cattle in Belgium (strain 543SA98) and France (strains BN10055, BN9945, and BN9181), and MDR serovar Typhimurium DT204 strains, showing a high level of resistance to fluoroquinolones, were isolated from cattle in Belgium (strain 902SA92) and from animal feed imported into Belgium from China (strain 102SA00). Susceptible serovar Typhimurium DT104 control strain S/921495 was isolated from cattle in Scotland. Susceptible serovar Typhimurium strain BN18 was isolated from a pigeon in France, and in vitro-selected, quinolone-resistant clones (strains BN18/21, BN18/41, and BN18/71) derived from this strain (4, 5, 6, 11). Additional strains used in this study were the susceptible serovar Typhimurium reference strain LT2, whose genome has completely been sequenced (GenBank accession number NC_003197) (18), and the *E. coli* cloning strain TG1.

All strains were cultivated at 37°C in Luria-Bertani (LB) or brain heart infusion medium. Mutants carrying the *kan* gene and transformants carrying the pBR1MCS2 vector were grown in the presence of kanamycin (Fluka Sigma-Aldrich, Saint-Quentin Fallavier, France) at 50 µg/ml.

MIC determination. Susceptibility testing was performed according to the guidelines of the CASFM (<http://www.sfm.asso.fr/nouv/general.php?pa=2>). The MICs of nalidixic acid (Fluka Sigma-Aldrich, Saint-Quentin Fallavier, France), flumequine (Sigma, St. Louis, MO), enrofloxacin (Vetoquinol, Lure, France), ciprofloxacin (Fluka Sigma-Aldrich, Saint-Quentin Fallavier, France), chloramphenicol (Fluka Sigma-Aldrich, Saint-Quentin Fallavier, France), florfenicol (Schering-Plough Animal Health, Kenilworth, NJ), and tetracycline (Fluka Sigma-Aldrich, Saint-Quentin Fallavier, France) were determined by the standard agar doubling dilution method as described previously (20).

Construction of the *marR*, *marA*, *soxR*, *soxS*, *ramR*, and *ramA* deletion mutants. The Datsenko and Wanner gene inactivation method (9) was used to create $\Delta marR::kan$, $\Delta marA::kan$, $\Delta soxR::kan$, $\Delta soxS::kan$, $\Delta ramR::kan$, and $\Delta ramA::kan$ mutants of the susceptible serovar Typhimurium DT104 strain S/921495 as described previously (6). Plasmid pKD4 carrying the *kan* gene was used as the plasmid template. The 50 nucleotides that are homologous to the gene to be inactivated and that extend to the pKD4-specific primers P1 and P2 (9) are listed in Table 2. The *ramA* mutation was further introduced into all serovar Typhimurium strains studied (Table 1) by transduction using phage P22 as described previously (4, 5, 6, 20). The resulting *ramA::kan* mutants were selected on LB plates containing 50 µg/ml of kanamycin. Replacement of the

target gene with the *kan* resistance gene was confirmed by PCR using the k2 and kt primers and primers flanking the deleted regions (Table 2) (9, 19). The *kan* resistance gene was eliminated from the S/921495 $\Delta ramR::kan$ strain by using the pCP20 helper plasmid, which acts on the repeated sites flanking the resistance gene (9).

Complementation with the *ramR* gene. The *ramR*-complementing plasmid was constructed as follows: the 934-bp *ramR* fragment generated by PCR using primers BamHI-*ramR*1 and EcoRI-*ramR*2 (Table 2) from the genomic DNA of strain S/921495 was digested with EcoRI and BamHI (Promega, Madison, WI), purified, and ligated into the EcoRI- and BamHI-digested broad-host-range plasmid vector pBR1MCS2 (17). The resulting recombinant plasmid was then electroporated into *E. coli* TG1 cells, with selection on LB agar plates containing 50 µg/ml of kanamycin. The cloned wild-type *ramR* gene was transferred into the serovar Typhimurium strains by transformation with the recombinant plasmid. The effect of complementation with the wild-type *ramR* gene was examined by determining antibiotic susceptibilities.

Detection of mutations in the *ramR* region. The presence of mutations in the region ranging from the 3' end of *ramR* to the 5' end of *ramA* was assessed by PCR (Fig. 1). The sequences of the primers used are shown in Table 2. PCR was performed with a 0.2 µM concentration of each primer, a 200 µM concentration of the deoxynucleoside triphosphates (dNTPs), 1× *Taq* buffer, and 1.25 U of *Taq* DNA polymerase. A single colony of each serovar Typhimurium strain was used as the template DNA. After a 5-min denaturation at 95°C, amplification was performed for 30 cycles of 1 min at 95°C, 2 min at 60°C, and 2 min at 72°C, with a final extension of 10 min at 72°C. The PCR products were sent for nucleotide sequencing to Genome Express (Meylan, France). Mutations in this amplified region were analyzed by using BLASTN (<http://www.ncbi.nlm.nih.gov/BLAST/>) and with multiple sequence alignments using CLUSTALW (<http://www.ebi.ac.uk/clustalw/>).

AcrA expression analysis by dot blotting. The dot blotting used in this study was adapted from a Western blot method previously described (11). Bacteria were grown at late exponential phase at 37°C in LB medium, harvested by centrifugation, and resuspended at an A_{600} of 10.0. Cells were diluted to one-half in the sample buffer of Laemmli and were heated for 10 min at 100°C. Whole-cell proteins were spotted onto a nitrocellulose membrane. The membrane was washed three times with Tris-buffered saline (TBS; 0.15% NaCl, 10 mM Tris-HCl [pH 7.5]), saturated for 30 min at room temperature with TBS containing 1% skim milk, and incubated overnight at room temperature with an anti-AcrA polyclonal antibody diluted 1/2,000 in TBS containing 0.33% skim milk. After three washes in TBS, the membrane was incubated for 1 h with peroxidase conjugated to protein A (Sigma, St. Louis, MO) diluted 1/1,000 in TBS. Finally, after three washes in TBS, the blot was revealed with the ECL detection system (GE Healthcare, Chalfont, United Kingdom). The capture of the chemiluminescence image was done by the Chemi-Smart system (Vilber-Lourmat, Marne-la-Vallée, France). The density of each dot was compared to that of the susceptible S/921495 control strain with the Bio1D++ software (Vilber-Lourmat, Marne-la-Vallée, France).

RT-PCR. Reverse transcription-PCR (RT-PCR) was used to assess the expression of *ramA*. Total RNA (1 µg), dNTPs (500 µM), and 50 ng of random hexamers (Promega, Madison, WI) were incubated for 5 min at 65°C, chilled on ice, and then reverse transcribed in a volume of 20 µl containing 0.01 M of dithiothreitol, 40 U of RNaseOUT RNase inhibitor (Invitrogen, Cergy-Pontoise, France), 200 U of Superscript II reverse transcriptase (Invitrogen, Cergy-Pontoise, France), and 1× first-strand buffer for 50 min at 42°C and then for 15 min at 70°C. Generated cDNA was incubated for 20 min at 37°C with 1 µl of RNase A (500 µg/ml; Qbiogene, Illkirch, France) and stored at –20°C until it was used. Differences in *ramA* gene expression were estimated by PCR, using the target-specific primers *ramA*3 and *ramA*4 (Table 2). Total cDNA (1 µl) was amplified in a 20-µl final volume containing a 0.5 µM concentration of each target-specific primer, a 250 µM concentration of the dNTPs, 1× *Taq* buffer, and 0.5 U of *Taq* DNA. Amplifications were performed with an initial step of 3 min at 95°C, followed by 35 cycles of 20 s at 95°C, 20 s at 58°C, and 20 s at 72°C. The constitutive expression of *gyrB* assessed in the same cDNA preparation was used as a control, using primers *gyrB*3 and *gyrB*4 (Table 2). PCR products were detected on 1.5% agarose gel containing ethidium bromide, and the level of gene overexpression was estimated by a comparison of the band intensities relative to those of twofold serial dilutions of cDNAs.

RESULTS

Lack of a role of MarR, MarA, SoxR, and SoxS in the MDR of serovar Typhimurium. Genes *marR*, *marA*, *soxR*, and *soxS*




FIG. 1. Sequence analysis of the *ramR-ramA* region in serovar Typhimurium strains. (A) Features of the 288-bp-long *ramA-ramR* intergenic region in serovar Typhimurium strain LT2. The predicted -10 and -35 promoter regions are underlined. The inverted repeat sequences are bold and indicated by arrows. The putative ribosome-binding site (RBS) is indicated with a dotted line. (B) Sequence alignment of the putative promoter region of serovar Typhimurium strains LT2 and BN10055 showing two nucleotide deletions in the putative RamR binding site of the latter strain. (C) Mutations found in the *ramR* gene in serovar Typhimurium strains BN18/21, BN18/41, BN18/71, BN9945, and 543SA98. nt, nucleotide. (D) Interruption by an IS1 element of the *ramR* gene in serovar Typhimurium DT204 strains 102SA00 and 902SA92.

TABLE 1. *Salmonella enterica* serovar Typhimurium strains used in this study^a

Strain	Phage type	Origin	SGI1	MIC of indicated quinolone (µg/ml)				MIC of indicated antibiotic (µg/ml)			Substitution(s) in the QRDR of:			Mutation in <i>acrR</i>	WB AcrA ratio	Source
				Nal	Flu	Enr	Cip	Cm	Ff	Tc	GyrA	GyrB	ParC			
MDR strains																
902SA92	DT204	B	-	>4,096	2,048	64	32	1,024	16	256	S83A, D87N	S464F	S80I	-	4	5
902SA92(pRamR)	DT204	B	-	4,096	512	16	8	256	4	256	S83A, D87N	S464F	S80I	-	1	This study
902SA92 $\Delta ramA::kan$	DT204	B	-	4,096	512	16	8	256	4	256	S83A, D87N	S464F	S80I	-	1	This study
102SA00	DT204	B	-	>4,096	2,048	64	32	512	16	256	S83A, D87N	S464F	S80I	-	4	5
102SA00(pRamR)	DT204	B	-	4,096	512	16	8	256	4	256	S83A, D87N	S464F	S80I	-	1	This study
102SA00 $\Delta ramA::kan$	DT204	B	-	4,096	512	16	8	256	4	256	S83A, D87N	S464F	S80I	-	1	This study
BN10055	DT104	F	+	>4,096	64	2	1	1,024	128	256	S83Y	-	-	-	4	6
BN10055(pRamR)	DT104	F	+	>4,096	64	2	1	1,024	128	256	S83Y	-	-	-	4	This study
BN10055 $\Delta ramA::kan$	DT104	F	+	512	16	0.5	0.25	128	32	64	S83Y	-	-	-	1	This study
543SA98	DT104	B	+	1,024	32	2	0.5	512	512	128	S83F	-	-	-	4	6
543SA98(pRamR)	DT104	B	+	512	8	0.5	0.125	128	128	32	S83Y	-	-	-	1	This study
543SA98 $\Delta ramA::kan$	DT104	B	+	512	8	0.5	0.125	128	128	32	S83Y	-	-	-	1	This study
BN9945	DT104	F	+	1,024	32	1	0.5	512	128	128	-	-	-	-	2	6
BN9945(pRamR)	DT104	F	+	512	8	0.25	0.125	128	64	32	-	-	-	-	1	This study
BN9945 $\Delta ramA::kan$	DT104	F	+	512	8	0.25	0.125	128	64	32	-	-	-	-	1	This study
BN9181	DT104	F	+	4	0.5	0.030	0.015	128	32	32	-	-	-	-	1	6
BN9181(pRamR)	DT104	F	+	4	0.5	0.030	0.015	128	32	32	-	-	-	-	1	This study
BN9181 $\Delta ramA::kan$	DT104	F	+	4	0.5	0.015	0.0075	128	32	32	-	-	-	-	1	This study
Control strains																
S/921495	DT104	S	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	6
S/921495 $\Delta marR::kan$	DT104	S	-	2	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495 $\Delta marR$	DT104	S	-	2	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495 $\Delta marA::kan$	DT104	S	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495 $\Delta soxR::kan$	DT104	S	-	2	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495 $\Delta soxS::kan$	DT104	S	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495(pRamR)	DT104	S	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495 $\Delta ramR::kan$	DT104	S	-	16	2	0.125	0.060	16	16	4	-	-	-	-	4	This study
S/921495 $\Delta ramR$	DT104	S	-	16	2	0.125	0.060	16	16	4	-	-	-	-	4	This study
S/921495 $\Delta ramR$ (pRamR)	DT104	S	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
S/921495 $\Delta ramA::kan$	DT104	S	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
BN18	ND	F	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	11
BN18(pRamR)	ND	F	-	4	0.5	0.030	0.015	4	4	1	-	-	-	-	1	This study
BN18 $\Delta ramA::kan$	ND	F	-	4	0.5	0.030	0.015	4	2	1	-	-	-	-	1	This study
BN18/21	ND	F	-	64	8	0.5	0.125	16	16	4	-	-	-	-	4	11
BN18/21(pRamR)	ND	F	-	8	2	0.125	0.060	4	4	1	-	-	-	-	1	This study
BN18/21 $\Delta ramA::kan$	ND	F	-	8	2	0.125	0.060	4	4	1	-	-	-	-	1	This study
BN18/41	ND	F	-	>4,096	256	4	2	32	64	8	G81C	-	-	+	6	11
BN18/41(pRamR)	ND	F	-	4,096	64	2	0.5	16	8	2	G81C	-	-	+	1	This study
BN18/41 $\Delta ramA::kan$	ND	F	-	4,096	64	2	0.5	16	8	2	G81C	-	-	+	1	This study
BN18/71	ND	F	-	>4,096	512	16	8	64	64	16	G81C	-	-	+	8	11
BN18/71(pRamR)	ND	F	-	4,096	256	4	2	16	8	2	G81C	-	-	+	1	This study
BN18/71 $\Delta ramA::kan$	ND	F	-	4,096	256	4	2	16	8	2	G81C	-	-	+	1	This study

^a ND, not determined; F, France; B, Belgium; S, Scotland; Nal, nalidixic acid; Flu, flumequine; Enr, enrofloxacin; Cip, ciprofloxacin; Cm, chloramphenicol; Ff, florfenicol; Tc, tetracycline; SGI1, *Salmonella* genomic island 1; WB, Western blot with anti-AcrA polyclonal antibody; +, presence; -, absence.

were inactivated in susceptible serovar Typhimurium DT104 strain S/921495. According to the MICs, none of these genes' susceptibilities to the quinolones nalidixic acid and flumequine, to the fluoroquinolones enrofloxacin and ciprofloxacin, to the phenicols chloramphenicol and florfenicol, and to tetracycline were affected (Table 1). The inactivation of these genes also did not affect *acrAB* expression, according to the dot blot results with an anti-AcrA polyclonal antibody (Table 1). These results suggest that the *mar* and *sox* regions are not involved in the regulation of the expression of *acrAB* and, consequently, of MDR in serovar Typhimurium.

Identification of *ramR* encoding a putative regulatory protein in serovar Typhimurium. Upstream of *ramA* in the serovar Typhimurium LT2 genome sequence (GenBank accession number NC_003197), the open reading frame STM0580, coding for a protein of 194 amino acids which, according to its amino acid sequence homology, belongs to the TetR family of transcriptional repressors (Fig. 1A), was detected. The gene is located in the orientation opposite to that of *ramA*, as is the

case for *acrR*, the local repressor gene of *acrAB*. Since open reading frame STM0580 might be the local repressor of *ramA*, it was named *ramR* in the present study. A putative RamR binding site was found upstream of *ramA* in the 288-bp-long *ramA-ramR* intergenic region corresponding to inverted repeat sequences downstream of the putative promoter region (Fig. 1A).

Characterization of *ramR*, coding for the local repressor of *ramA* in serovar Typhimurium. Inactivation of the putative repressor gene upstream of *ramA* in the susceptible serovar Typhimurium DT104 strain S/921495 resulted in an MDR phenotype, with fourfold increases in the MICs of nalidixic acid, flumequine, enrofloxacin, ciprofloxacin, chloramphenicol, florfenicol, and tetracycline. Complementation with a plasmid containing the wild-type gene restored the initial susceptibilities of the strain. The inactivation of the putative repressor gene also resulted in a fourfold-increased expression of *ramA*, as shown by RT-PCR (Fig. 2), and a fourfold-increased expression of the AcrAB efflux pump, according to the AcrA dot

TABLE 2. Primers used for PCRs

Primer use and target region	Primer(s)	Nucleotide position ^a	Oligonucleotide sequence(s) (5' to 3')	Annealing temp (°C)
Construction of deletion mutants <i>ramA-kan</i>	ramAH1-P1	639041	ACACGATTGTCGAGTGGATTGATGATAATTTGAAT CAGCCGTTAC-GTGTAGGCTGGAGCTGCTTC	52
	ramAH2-P2	639285	ACGATAAGCGCCTGGCGGCAGGTTGAACGTGCGG GTAAAAATGCG-CATATGAATATCCTCCTTAG	52
<i>ramR-kan</i>	ramRH1-P1	638183	TCGAATCCCAGCGCAATATATTCGCCAGCGCGAGC GGGATCGCGC-GTGTAGGCTGGAGCTGCTTC	52
	ramRH2-P2	638650	AAGCATTACTGGAAGCGCAACCCAGGCGAAACG CAATCCGGTAT-CATATGAATATCCTCCTTAG	52
<i>marA-kan</i>	marAH1-P1	1597108	GGTTCAGCGGCAGCATATACCGTGATTCCGCATGC ATATT-GTGTAGGCTGGAGCTGCTTC	52
	marAH1-P2	1597328	TTCCAAATGGCACCTGCAACGGATGTTTAAAAAAG AGACC-CATATGAATATCCTCCTTAG	52
<i>marR-kan</i>	marRH1-P1	1597517	GCAAATACTCAAGCGTTGCCACTTCGTCCGCCGTT AAGTT-GTGTAGGCTGGAGCTGCTTC	52
	marRH2-P2	1597796	TTATCCCCGCTGGATATCACCAGCAACACAGTTAA AGTGC-CATATGAATATCCTCCTTAG	52
<i>soxS-kan</i>	soxSH1-P1	4503981	GACGGTAATCGCTGGGAGTGCATCGAACTCGCG GCGGAA-GTGTAGGCTGGAGCTGCTTC	52
	soxSH2-P2	4504210	TGAACATATCGACCAACCGCTAAACATTGATGTGG TGGCA-CATATGAATATCCTCCTTAG	52
<i>soxR-kan</i>	soxRH1-P1	4504393	CTCCCCGTTTAAAAAGCCTTACTGACGCCGGGGAA GTTGC-GTGTAGGCTGGAGCTGCTTC	52
	soxRH2-P2	4504767	CCCGTTCGCCAAGCCTGTCGCCTGGATTCGCA GCGGA-CATATGAATATCCTCCTTAG	52
Construction of complementation plasmid pRamR <i>ramR</i>	BamHI-ramR1	638092	CATGGGATCC-CGTGTCGATAACCTGAGCGG	62
	EcoRI-ramR2	639026	CTAGGAATTC-AAGGCAGTTCAGCGCAAAG	62
Detection of mutations <i>ramR-ramA</i>	ramR1	638092	CGTGTTCGATAACCTGAGCGG	62
	ramR2	639026	AAGGCAGTTCAGCGCAAAG	62
RT-PCR expression analysis <i>ramA</i>	ramA3	639043	CACGATTGTCGAGTGGATTG	58
	ramA4	639275	AAAATGCGCGTAAAGGTTTG	58
<i>gyrB</i>	gyrB3	4040174	TACCTGCTGGAAAACCCATC	58
	gyrB4	4039810	CTTGTCCGGGTTGTACTCGT	58

^a Nucleotide position according to the complete genome of *S. enterica* serovar Typhimurium LT2 (GenBank accession number NC_003197).




FIG. 2. RT-PCR analysis of *ramA* and *gyrB* (control) expression in serovar Typhimurium wild-type strain S/921495 (lane 1), deletion mutant strains S/921495 $\Delta ramR::kan$ (lane 2) and S/921495 $\Delta ramR$ (lane 3), and the complemented strain S/921495 $\Delta ramR(pRamR)$ (lane 4).

blot results (Table 1). Complementation with the wild-type gene restored the basal levels of expression of *ramA* (Fig. 2) and AcrA (Table 1). These results indicated that the gene encodes a local repressor of *ramA*, and thus, the designation *ramR* was justified.

The inactivation of *ramA* in serovar Typhimurium DT104 strain S/921495 did not affect its susceptibilities to nalidixic acid, flumequine, enrofloxacin, ciprofloxacin, chloramphenicol, florfenicol, and tetracycline and also did not affect the expression of the AcrAB efflux pump (Table 1). This can be explained by the fact that the expression of *ramR* is the major cause of the downregulation of *ramA* expression and, consequently, of *acrAB* expression.

Identification of mutations in *ramR* and in the regulatory region of *ramA* participating in the MDR of serovar Typhimurium. To date, we have not found any mutations in the *mar* or *sox* region that may explain the overexpression of *acrAB* in a set of previously studied MDR serovar Typhimurium strains that are also quinolone or fluoroquinolone resistant (Table 1) (4, 5, 6, 11, 19, 20). Since, in contrast to *mar* and *sox*, the *ram* region appears to play a major role in the regulation of *acrAB* expression, we looked for mutations in *ramR* and in the *ramR-ramA* intergenic region in this set of strains. As shown in Fig. 1, in all strains studied, several point mutations which resulted in amino acid changes or in a frameshift were identified in *ramR* (Fig. 1C). In addition, the interruption of *ramR* by an IS1 element was seen in high-level fluoroquinolone-resistant serovar Typhimurium DT204 strains (Fig. 1D). One serovar Typhimurium DT104 isolate had a 2-nucleotide deletion in the putative RamR binding site found upstream of *ramA* (Fig. 1B). These mutations were confirmed to play a role in the MDR phenotype by complementation with the wild-type *ramR* gene or inactivation of their respective *ramA* genes (Table 1). Interestingly, in MDR DT104 strains overexpressing *acrAB* and carrying the *Salmonella* genomic island 1-borne *floR* and *tet(G)* phenicol and tetracycline efflux pump genes, respectively, the inactivation of the *ramA* gene resulted in two- to fourfold decreases in levels of resistance to chloramphenicol, florfenicol, and tetracycline. In a previous study, we had shown that there was interplay between the FloR, Tet(G), and AcrAB efflux pumps to obtain high levels of resistance to phenicol and tetracycline (6).

DISCUSSION

Following a study using the salicylate induction of *marA*, it has been suggested that efflux-mediated MDR resistance in serovar Typhimurium may occur by both *mar*-dependent and *mar*-independent pathways (25). In another study on the bile salt-mediated induction of antimicrobial and bile resistance in serovar Typhimurium, it was concluded that while the transcription of *acrAB* was activated by bile, this activation was independent of *marRAB* (23). It was also observed that there was no correlation between cyclohexane tolerance in the multiple-antibiotic-resistant mutants of 14 different *S. enterica* serovars and the overexpression of *acrB*, *soxS*, or *marA* (32). In a more recent study on the selection of ciprofloxacin-resistant serovar Typhimurium, it was suggested that neither *marA* nor *soxS* is critical for *S. enterica* to generate a multiple-antibiotic-resistant mutant (26). Besides, no mutations in the *mar* region that would explain the overexpression of *acrAB* in serovar Typhimurium have been described to date (19, 24). In the case of the *sox* region, Koutsolioutsou et al. have shown that a clinical isolate of serovar Typhimurium became resistant by a point mutation in *soxR* (15). However, the mechanism by which this MDR resistance was conferred was not examined, and whether *soxR* influenced the expression of AcrAB or another efflux pump was not explored (21). For all these reasons, we reexamined the roles of the *mar* and *sox* regions by inactivating the *marR*, *marA*, *soxR*, and *soxS* genes in serovar Typhimurium DT104 strain S/921495. The inactivation of these genes did not alter the strain's susceptibilities to quinolones, fluoroquinolones, phenicol, and tetracycline. There was also

no effect on AcrA production. Our results thus indicated that in contrast to the situation in *E. coli*, the *mar* or *sox* region likely does not play a significant role in the efflux-mediated MDR phenotype via the overexpression of *acrAB* in serovar Typhimurium.

In *Salmonella* spp. and in other bacteria, such as *E. aerogenes*, *E. cloacae*, and *K. pneumoniae*, RamA, a homologue of MarA that is absent in *E. coli*, has been shown to be implicated in MDR, and the overexpression of *ramA* correlated well with an increased AcrAB efflux pump expression (7, 12, 13, 27–30, 33). In this study, the inactivation of *ramR* and complementation experiments with DT104 strain S/921495 confirmed that it codes for the local repressor of *ramA*, as we observed fourfold increases in the MICs of the antibiotics tested, which correlated well with the fourfold overexpression of *ramA* and also with the fourfold overproduction of AcrA. However, the inactivation of *ramA* in the control strain S/921495 did not affect antibiotic susceptibilities or AcrA production. Most probably, the expression of *ramA* is basal, and to affect antibiotic susceptibilities, the local repressor RamR must be affected either by an as-yet-unknown mechanism or by mutations in the *ramR* gene or in the RamR binding region. Therefore, we investigated the presence and role of mutations in the *ramR* region of a set of quinolone- or fluoroquinolone-resistant serovar Typhimurium strains previously shown to overproduce AcrAB (4, 5, 6, 11, 19, 20). Complementation experiments with the wild-type *ramR* gene confirmed that the mutations identified were critical for the RamR repressor function according to the decreased MICs of quinolones and fluoroquinolones observed as well as to the decreased AcrA production observed (Table 1). On the other hand, the inactivation of *ramA* in these strains also resulted in two- to fourfold reductions in the MICs of quinolones and fluoroquinolones (Table 1). All these data indicate that mutations in the *ramR* region may result in an up-to-fourfold increase in levels of resistance to unrelated antibiotics via *ramA* and *acrAB* overexpression. With additional mutations in *acrR*, as in serovar Typhimurium strains BN18/41 and BN18/71, the resistance levels and *acrAB* overexpression may increase up to eightfold (Table 1).

In conclusion, efflux-mediated MDR resistance in serovar Typhimurium via the overexpression of *acrAB* is assumed to be due mainly to what we can now call the *ram* regulon, whereas the *mar* and *sox* regions do not seem to play a significant role in this resistance. Probably, as with the *mar* regulon in *E. coli*, the *ram* regulon in serovar Typhimurium may be involved in the regulation of other genes; the first example is the flavohemoglobin (*hmp*) gene (12), and this should be further investigated by global transcriptomic or proteomic approaches.

ACKNOWLEDGMENT

We thank C. Mouline for his expert technical assistance.

REFERENCES

1. Alekshun, M. N., and S. B. Levy. 1997. Regulation of chromosomally mediated multiple antibiotic resistance: the *mar* regulon. *Antimicrob. Agents Chemother.* **41**:2067–2075.
2. Alekshun, M. N., and S. B. Levy. 1999. The *mar* regulon: multiple resistance to antibiotics and other toxic chemicals. *Trends Microbiol.* **7**:410–413.
3. Barbosa, T. M., and S. B. Levy. 2000. Differential expression of over 60 chromosomal genes in *Escherichia coli* by constitutive expression of MarA. *J. Bacteriol.* **182**:3467–3474.
4. Baucheron, S., E. Chaslus-Dancla, and A. Cloeckaert. 2004. Role of TolC

- and *parC* mutation in high-level fluoroquinolone resistance in *Salmonella enterica* serotype Typhimurium DT204. *J. Antimicrob. Chemother.* **53**:657–659.
5. **Baucheron, S., H. Imberechts, E. Chaslus-Dancla, and A. Cloeckaert.** 2002. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in *Salmonella enterica* serovar Typhimurium phage type DT204. *Microb. Drug Resist.* **8**:281–289.
 6. **Baucheron, S., S. Tyler, D. Boyd, M. R. Mulvey, E. Chaslus-Dancla, and A. Cloeckaert.** 2004. AcrAB-TolC directs efflux-mediated multidrug resistance in *Salmonella enterica* serovar Typhimurium DT104. *Antimicrob. Agents Chemother.* **48**:3729–3735.
 7. **Chollet, R., J. Chevalier, C. Bollet, J.-M. Pages, and A. Davin-Regli.** 2004. RamA is an alternate activator of the multidrug resistance cascade in *Enterobacter aerogenes*. *Antimicrob. Agents Chemother.* **48**:2518–2523.
 8. **Cloeckaert, A., and E. Chaslus-Dancla.** 2001. Mechanisms of quinolone resistance in *Salmonella*. *Vet. Res.* **32**:291–300.
 9. **Datsenko, K. A., and B. L. Wanner.** 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. USA* **97**:6640–6645.
 10. **Giraud, E., S. Baucheron, and A. Cloeckaert.** 2006. Resistance to fluoroquinolones in *Salmonella*: emerging mechanisms and resistance prevention strategies. *Microbes Infect.* **8**:1937–1944.
 11. **Giraud, E., A. Cloeckaert, D. Kerboeuf, and E. Chaslus-Dancla.** 2000. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in *Salmonella enterica* serovar Typhimurium. *Antimicrob. Agents Chemother.* **44**:1223–1228.
 12. **Hernandez-Urzu, E., D. S. Zamorano-Sanchez, J. Ponce-Coria, E. Morett, S. Grogan, R. K. Poole, and J. Membrillo-Hernandez.** 2007. Multiple regulators of the flavohaemoglobin (*hmp*) gene of *Salmonella enterica* serovar Typhimurium include RamA, a transcriptional regulator conferring the multidrug resistance phenotype. *Arch. Microbiol.* **187**:67–77.
 13. **Keeney, D., A. Ruzin, and P. A. Bradford.** 2007. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in *Enterobacter cloacae*. *Microb. Drug Resist.* **13**:1–6.
 14. **Kern, W. V., M. Oethinger, A. S. Jellen-Ritter, and S. B. Levy.** 2000. Non-target gene mutations in the development of fluoroquinolone resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.* **44**:814–820.
 15. **Koutsolioutsou, A., E. A. Martins, D. G. White, S. B. Levy, and B. Demple.** 2001. A *soxRS*-constitutive mutation contributing to antibiotic resistance in a clinical isolate of *Salmonella enterica* (serovar Typhimurium). *Antimicrob. Agents Chemother.* **45**:38–43.
 16. **Koutsolioutsou, A., S. Peña-Llopis, and B. Demple.** 2005. Constitutive *soxR* mutations contribute to multiple-antibiotic resistance in clinical *Escherichia coli* isolates. *Antimicrob. Agents Chemother.* **49**:2746–2752.
 17. **Kovach, M. E., P. H. Elzer, D. S. Hill, G. T. Robertson, M. A. Farris, R. M. Roop II, and K. M. Peterson.** 1995. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. *Gene* **166**:175–176.
 18. **McClelland, M., K. E. Sanderson, J. Spieth, S. W. Clifton, P. Latreille, L. Courtney, S. Porwollik, J. Ali, M. Dante, F. Du, S. Hou, D. Layman, S. Leonard, C. Nguyen, K. Scott, A. Holmes, N. Grewal, E. Mulvaney, E. Ryan, H. Sun, L. Florea, W. Miller, T. Stoneking, M. Nhan, R. Waterston, and R. K. Wilson.** 2001. Complete genome sequence of *Salmonella enterica* serovar Typhimurium LT2. *Nature* **413**:852–856.
 19. **Olliver, A., M. Vallé, E. Chaslus-Dancla, and A. Cloeckaert.** 2004. Role of an *acrR* mutation in multidrug resistance of *in vitro*-selected fluoroquinolone-resistant mutants of *Salmonella enterica* serovar Typhimurium. *FEMS Microbiol. Lett.* **238**:267–272.
 20. **Olliver, A., M. Vallé, E. Chaslus-Dancla, and A. Cloeckaert.** 2005. Overexpression of the multidrug efflux operon *acrEF* by insertional activation with *IS1* or *IS10* elements in *Salmonella enterica* serovar Typhimurium DT204 *acrB* mutants selected with fluoroquinolones. *Antimicrob. Agents Chemother.* **49**:289–301.
 21. **Piddock, L. J. V.** 2002. Fluoroquinolone resistance in *Salmonella* serovars isolated from humans and food animals. *FEMS Microbiol. Rev.* **26**:3–16.
 22. **Piddock, L. J. V.** 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin. Microbiol. Rev.* **19**:382–402.
 23. **Prouty, A. M., I. E. Brodsky, S. Falkow, and J. S. Gunn.** 2004. Bile-salt-mediated induction of antimicrobial and bile resistance in *Salmonella typhimurium*. *Microbiology* **150**:775–783.
 24. **Randall, L. P., S. W. Cooles, L. J. V. Piddock, and M. J. Woodward.** 2004. Effect of triclosan or a phenolic farm disinfectant on the selection of antibiotic-resistant *Salmonella enterica*. *J. Antimicrob. Chemother.* **54**:621–627.
 25. **Randall, L. P., and M. J. Woodward.** 2001. Multiple antibiotic resistance (*mar*) locus in *Salmonella enterica* serovar Typhimurium DT104. *Appl. Environ. Microbiol.* **67**:1190–1197.
 26. **Ricci, V., P. Tzakas, A. Buckley, N. C. Coldham, and L. J. V. Piddock.** 2006. Ciprofloxacin-resistant *Salmonella enterica* serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. *Antimicrob. Agents Chemother.* **50**:38–42.
 27. **Ruzin, A., M. A. Visalli, D. Keeney, and P. A. Bradford.** 2005. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **49**:1017–1022.
 28. **Schneiders, T., S. G. B. Amyes, and S. B. Levy.** 2003. Role of AcrR and RamA in fluoroquinolone resistance in clinical *Klebsiella pneumoniae* isolates from Singapore. *Antimicrob. Agents Chemother.* **47**:2831–2837.
 29. **van der Straaten, T., R. Janssen, D. J. Mevius, and J. T. van Dissel.** 2004. *Salmonella* gene *rma* (*ramA*) and multiple-drug-resistant *Salmonella enterica* serovar Typhimurium. *Antimicrob. Agents Chemother.* **48**:2292–2294.
 30. **van der Straaten, T., L. Zuilanello, A. van Diepen, D. L. Granger, R. Janssen, and J. T. van Dissel.** 2004. *Salmonella enterica* serovar Typhimurium RamA, intracellular oxidative stress response, and bacterial virulence. *Infect. Immun.* **72**:996–1003.
 31. **Velge, P., A. Cloeckaert, and P. Barrow.** 2005. Emergence of *Salmonella* epidemics: the problems related to *Salmonella enterica* serotype Enteritidis and multiple antibiotic resistance in other major serotypes. *Vet. Res.* **36**:267–288.
 32. **Webber, M., A. M. Buckley, L. P. Randall, M. J. Woodward, and L. J. V. Piddock.** 2006. Overexpression of *marA*, *soxS* and *acrB* in veterinary isolates of *Salmonella enterica* rarely correlates with cyclohexane tolerance. *J. Antimicrob. Chemother.* **57**:673–679.
 33. **Yassien, M. A., H. E. Ewis, C.-D. Lu, and A. T. Abdelal.** 2002. Molecular cloning and characterization of the *Salmonella enterica* serovar Paratyphi B *rma* gene, which confers multiple drug resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.* **46**:360–366.